Canadian Journal of Infectious Diseases and Medical Microbiology

Canadian Journal of Infectious Diseases and Medical Microbiology / 2006 / Article

Open Access

Volume 17 |Article ID 703782 |

Coleman Rotstein, "Hospital-Acquired Methicillin-Resistant Staphylococcus aureus: Epidemiology, Treatment and Control", Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 17, Article ID 703782, 6 pages, 2006.

Hospital-Acquired Methicillin-Resistant Staphylococcus aureus: Epidemiology, Treatment and Control


Antimicrobial-resistant organisms are an expanding problem, resulting in increased morbidity and mortality, prolonged hospital stay, and heightened health care costs for care and antimicrobial management. Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major hospital-acquired, antimicrobial-resistant pathogen. MRSA not only colonizes hospitalized patients but has a propensity to produce more serious, life- threatening infection than methicillin-susceptible strains. Numerous risk factors, including antimicrobial use and proximity to a patient harbouring MRSA, have been linked to the acquisition of MRSA. Although vancomycin has been the mainstay of therapy for MRSA, failures have been reported due to reduced susceptibility to this agent. Other available therapeutic agents for MRSA include trimethoprim-sulfamethoxazole, tetracycline, fusidic acid, rifampin (in combination with other effective agents) and linezolid. Potential therapeutic agents that are currently under investigation include daptomycin, dalbavancin, tigecycline, ceftobiprole and iclaprim. Only enhanced infection control practices can halt the progressive transmission of MRSA in the hospital environment. However, such measures have not quite fulfilled their promise in clinical studies. Moreover, eradication of MRSA colonization is controversial and may promote greater resistance. A multidisciplinary approach to the prevention, containment and treatment of MRSA is necessary.

Copyright © 2006 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.